- Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F. and Stashenko, P. (1981) "A unique cell surface antigen identifying lymphoid malignancies of B cell origin", J. Clin. Investig. 67, 134-140.
- Miller, R.A., Maloney, D.O., Warnke, R. and Levy, R. (1982) "Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody", N. Engl. J. Med. 306, 517-522,
- Reff, M.E., Carner, FC, Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. and Anderson, D.R. (1994) "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood 83, 435-445.
- Maloney, D.O., Liles, T.M., Czerwinski, O.K., Waldichuk, C. Rosenberg, J., Grillo-Lopez, A. and Levy, R. (1994) "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood 84, 2457-2466.
- Maloney, D., Smith, B. and Appelbaum, F. (1996) "The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines abstract", Blood 94, 2535a.
- Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs", Cancer Biother. Radiopharm. 12, 177-186
- Shan, D., Ledbetter, J.A. and Press, O.W. (1998) "Apoptosis of malignant human B cells by ligabon of CD20 with monoclonal antibodies", Blood 91, 1644 -1652.
- Gansow, O.A., Brechbiel, M.W., Mirzadeh, S., Colcher, D. and Roselli, M. (1990) "Chelates and antibodies: current methods and new directions", Cancer Treat. Res. 51, 153-171.
- Gordon, L., White, C and Witzig, T. (1999) "Zevalin (IDEC-Y2B8) radioimmunotherapy of rituximab refractory follicular nonHodgkin's lymphoma (NHL): Interim Results", Blood 94, 396a. abstract.
- Witzig, T., White. C. and Gordon, L. (1999) "Prospective, randomized controlled study of Zevaiin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for Bcell NHL: report of interim results (abstract)", Blood 94, 631a.
- Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., childer, R.J., Spies, S., Silverman, D.H., Parker, E. and Grillo-Lopez, A.J. (1999) "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma", J. Clin. Oncol. 17, 3793-3803.
- Smith, P.C. and Doll, R. (1976) "Late effects of x irradiation in patients treated for metropathia haemorrhagica", Br. J. Radiol. 49, 224-232.
- Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., Zelenetz, A.D., Tidmarsh, G.E. Stagg, R.J. and Kaminski, M.S (2000) "Multicenter phase II study of iodine-131 tosituniomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol. 18, 1316-1323.
- Kaminski, M., Zelenetz, A. and Press, O. (1998) "Multi-center phase m study of Iodine-131 tositumomab (anti-81 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) (abstract)", Blood 92, 1296a.
- Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G. and Wahl, R.L. (2000) "Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood. 96, 1259 1266.
- Press, O., Eary, J and Liu, S. (1998) "A phase I/II trial of high-dose iodine 131 anti-B1 (anti-CD20) monoclonal antibody, etoposide. cyclophosphomide, and autologous stem-cell transplantation for patients with relapsed B-cell lymphomas", Proc. Am. Soc. Clin. Oncol. 17, 19a. abstract.
- Press, O.W. (1999) "Radiolabeled antibody therapy of B-cell lymphomas", Semin. Oncol. 26, 58-65.
- Thirman, M.J. and Larson, R.A. (1996) "Therapy-related myeloid leukemia", Hematol. Ortcol. Clin. N. Am. 10, 293-320.
- Leone, G., MeIe, L., Pulsoni, A., Equitani, F. and Pagano, L. (1999) 'The incidence of secondary leukemias", Haematologica 84, 937-945.
- Super, H.J., McCabe, N.R., Thirman, M.J., Larson, R.A., Le Beau, MM., Pedersen-Bjergaard, J., Philip, P., Diaz, M.O. and Rowley, J.D. (1993) "Rearrangeinenls of the MLL gene in therapy-related acute mycloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II", Blood 82, 3705-3711.
- Hunger, S.P., Tkachuk, D.C., Amylon, M.D., Link, M.P., Carroll. A.J., Welbom, J.L., Willman.,CL. and Cleary. M.L. (1993) "HRX involvement in de novo and secondary leukemias with diverse chromosome 1 Iq23 abnormalities", Blood 81, 3197-3203.
- Starostik, P., Greiner, A., Schultz, A., Zettl, A., Peters, K., Rosenwald, A., Kolve, M. and Muller-Hermelink, H.K. (2000) "Genetic aberrations common in gastric high-grade large B-cell lymphoma", Blood 95, 1180-1187.
- Zhu, Y., Monni, O., Franssila, K., Elonen, F., Vilpo, J., Joensuu, H. and Knuutila, S. (2000) "Deletions at 11q23 in different lymphoma subtypes", Haematologica 85, 908-912
- Cuneo, A., Bigoni, R., Rigolin, G.M., Roberti, M.G., Milani, R.,Bardi, A., Minotto, C., Agostini, P., De Angeli, C, Narducci, M.G., Sabbioni, S., Russo, G., Negrini, M. and Castoldi, G. (2000) "Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features", J. Clin. Oncol. 18, 2607-2614.
- Taylor, H.J., Graven, P. and Plowman, RN. (2000) "Secondary acute myeloblastic leukaemia (AML) (expressing 11q23 mutation) occurring 11 months after chemotherapy/radiotherapy for pediatrics non-Hodgkin lymphoma (NHL)", Clin. Oncol. 12, 112-114.
Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's Lymphoma
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.